Claims
- 1. A process for preventing coagulation of blood, which comprises administering to a subject in need thereof, an effective amount of anti-coagulant comprising as an active component, a substantially pure polypeptide consisting essentially of the amino acid sequence shown in FIG. 1.
- 2. The process according to claim 1, wherein the anticoagulant compound is administered in the form of an injection.
- 3. The process according to claim 1, wherein the anticoagulant compound is lyophilized and dissolved in distilled water.
- 4. The process according to claim 1, wherein the anticoagulant compound is lyophilized and dissolved in physiological saline.
- 5. The process according to claim 2, wherein the route of injection is intravaneous.
- 6. The process according to claim 1, wherein the amount per subject of the polypeptide ranges from 10 micrograms to 10 mg/kg per day.
- 7. The process according to claim 1, wherein said subject is in need of said process due to cerebral infarction or myocardial infarction.
Priority Claims (1)
Number |
Date |
Country |
Kind |
63-182633 |
Jul 1988 |
JPX |
|
Parent Case Info
This application is a continuation of application Ser. No. 07/379,266, filed on Jul. 13, 1989.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4873222 |
Arai |
Oct 1989 |
|
Non-Patent Literature Citations (1)
Entry |
Crompton et al "Primary Structure of the human, membrane-associated Ca.sup.2+ . . . "EMBO v. 7, No. 1 pp. 21-27 Jan. 1988. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
379266 |
Jul 1989 |
|